Preclinical characterization of substituted 6,7-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-8(5H)-one P2X7 receptor antagonists

详细信息    查看全文

• 作者：Michael K. Ameriks ; Hong Ao ; Nicholas I. Carruthers ; Brian Lord ; Suchitra Ravula ; Jason C. Rech ; Brad M. Savall ; Jessica L. Wall ; Qi Wang ; Anindya Bhattacharya ; Michael A. Letavic
• 关键词：P2X7 ; 6 ; 7-Dihydro-[1 ; 2 ; 4]triazolo[4 ; 3-a]pyrazin-8(5H)-one ; Autoradiography ; Depression ; CNS
• 刊名：Bioorganic & Medicinal Chemistry Letters
• 出版年：2016
• 出版时间：15 January 2016
• 年：2016
• 卷：26
• 期：2
• 页码：257-261
• 全文大小：2201 K

文摘

The synthesis, SAR, and preclinical characterization of a series of substituted 6,7-dihydro[1,2,4]triazolo[4,3]pyrazin-8(5H)-one P2X7 receptor antagonists are described. Optimized leads from this series comprise some of the most potent human P2X7R antagonists reported to date (IC₅₀s < 1 nM). They also exhibit sufficient potency and oral bioavailability in rat to enable extensive in vivo profiling. Although many of the disclosed compounds are peripherally restricted, compound 11d is brain penetrant and upon oral administration demonstrated dose-dependent target engagement in rat hippocampus as determined by ex vivo receptor occupancy with radiotracer 5 (ED₅₀ = 0.8 mg/kg).